Posted on

Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect associated with anticancer drugs.45 Nearly 70% of cancer patients experience neuropathic pain symptoms due to the administration of anticancer drugs such as platinum compounds, proteasomes inhibitors, and antitubulins (e.g., vinca alkaloids and taxanes).11,59 Paclitaxel is the frontline chemotherapeutic agent used to treat many solid tumors, but it is also associated with a high incidence of CIPN leading to dose reduction or termination of an otherwise potential life-saving treatment.

Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice

Orginally Published At: Pain Journal

Leave a Reply

Your email address will not be published. Required fields are marked *